The strong quarterly revenue growth and cash preservation validate the commercial launch trajectory for Ryoncil. Monitor upcoming quarterly filings for continued site adoption and patient start acceleration, as well as pipeline catalysts for rexlemestrocel-L (CLBP, CHF) and adult SR-aGvHD expansion.
Price Chart
Executive Summary
Mesoblast reported a 44% increase in Ryoncil net revenue to $28M for the first fiscal quarter ended September 30, 2026, compared to $19M in the prior year period, and an 85% improvement in net operating cash spend to $2.3M from $14.9M. The company ended the quarter with a strong cash position of $99M. September saw the highest number of new patient starts per month, indicating continued commercial adoption following the December 2024 FDA approval.
Key Facts
- Net revenue from Ryoncil sales increased 44% to US$28 million in Q1 FY2026 vs US$19 million in prior year period
- Net operating cash spend improved 85% to US$2.3 million from US$14.9 million
- Cash position of US$99 million at September 30, 2026
- September recorded the highest number of new patient starts per month
- 54 onboarded sites for Ryoncil commercial rollout
Financial Impact
44% revenue growth to $28M and 85% cash burn reduction to $2.3M in Q1 FY2026
Risk Factors
- Company remains unprofitable with accumulated losses of $1.07B per the annual 20-F
- Revenue concentration in a single product (Ryoncil) for pediatric SR-aGvHD
- Pipeline candidates (rexlemestrocel-L) face ongoing clinical and regulatory risks
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000091 |
| Exhibit: exhibit991ryoncilsalesup.htm | 0001345099-26-000091 |
| Document: 0001345099-26-000091-index-headers.html | 0001345099-26-000091 |
| Document: 0001345099-26-000091-index.html | 0001345099-26-000091 |
| Document: 0001345099-26-000091.txt | 0001345099-26-000091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $13.28 $11.95 | ▼ −10.02% | ▼ −10.44% | $12.39 (−6.70%) |
Oct 15, 2026 12d ago | 6-K | $13.95 $13.28 | ▼ −4.80% | ▼ −3.70% | $12.39 (−11.18%) |
Oct 13, 2026 14d ago | 6-K | $13.90 $13.79 | ▼ −0.76% | ▲ +0.33% | $12.39 (−10.83%) |
Sep 23, 2026 4w ago | 6-K | $15.48 $15.12 | ▼ −2.33% | ▼ −2.87% | $12.39 (−19.96%) |
Aug 27, 2026 8w ago | 20-F | $18.18 $17.44 | ▼ −4.07% | ▼ −3.84% | $12.39 (−31.85%) |
Aug 26, 2026 8w ago | Press Release | $18.18 $17.44 | ▼ −4.07% | ▼ −3.84% | $12.39 (−31.85%) |
Aug 24, 2026 9w ago | 6-K | $16.64 $17.19 | ▲ +3.31% | ▲ +2.99% | $12.39 (−25.54%) |
Aug 16, 2026 10w ago | Press Release | $17.02 $16.67 | ▼ −2.06% | ▼ −1.38% | $12.39 (−27.20%) |
Jul 30, 2026 12w ago | 6-K | $14.55 $14.17 | ▼ −2.61% | ▼ −3.32% | $12.39 (−14.85%) |
Jul 14, 2026 15w ago | 6-K | $16.74 $18.24 | ▲ +8.96% | ▲ +8.56% | $12.39 (−25.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers